This message was sent to ##Email##
At the 2018 ASHI Annual Business Meeting held in Baltimore, MD, ASHI's Past President Dr. John Schmitz revealed ASHI's Strategic Planning initiatives for 2019.
Click here for a quick video of the 5 Strategic Planning initiatives.
ASHI congratulates the September ABHI CHS, CHT and Diplomate certificate recipients!
Brooke C. Banuelos
Jacqueline Michelle Buck
Carrie Lynn Butler
Ana Rusela D. Calizo
Kathleen Mary Delagorgendiere
Khalid Elsiddig El Faki
Keelan L. Elliott-Garcia
Jennifer Bosse Gerfen
Melissa Lynne Glenn
Ashley E. Kosowicz
Thomas Joseph Morris
Timothy Robert O'Neill
Sasun Maxime Orak
Melissa J. Personius
Kimberly Ann Pfau
Amy Nicole Reynolds
Jessica R. Scioletti
Carolyn Marie Teslenko
Tiffany R. Baker
John Edward Chappelle
Erik Nathaniel Chatroop
Christopher Andrew Dougherty
Catherine Abigail Hardy
Kylie Beth Peck
Melissa Maria Reed
Andres A. Rondon
Julie Anne Seiwert
Dr. Caroline Alquist
Dr. Po-Chien Chou
Dr. Daniel Graziano
Dr. Anna Greenshields
Dr. Abdelhamid Liacini
Dr. Ping Rao
Dr. Bobbie Rhodes-Clark
Dr. Abubaker Sidahmed
Dr. New New Soe
Dr. Harold Sullivan
Dr. Amena Usmani
HLA Typing, NGS, almost no ambiguity, Affordable, Accurate, Quick turnaround time. Reports are uploaded to compatible laboratory software. HLA antibody identification by SAB or C1q, KIR typing, Cancer gene screening and many more.
Questions regarding our testing or to discuss your needs, please contact us at 972-566-8478, 972-566-6278 or 972-566-5761 or visit our website at texasmedicalspecialty.com.
United Network for Organ Sharing (UNOS) has again won a competitive federal contract to serve as the nation's Organ Procurement and Transplantation Network (OPTN). UNOS has fulfilled this role since the OPTN began in 1986, under contract with the Health Resources and Services Administration of the U.S. Department of Health and Human Services (HHS).
"UNOS is committed to continually improving the nation's transplant system," said UNOS Chief Executive Officer Brian Shepard. "Donors, their families, and waiting transplant candidates depend on us."
Click here to read the full article.
The Paul I. Terasaki Antibody Symposium will be held on July 19 – 30, 2019 in Los Angeles, California. Additional details will be provided soon.
For more information, email firstname.lastname@example.org.
Have you renewed your ASHI membership for 2019? If not, do it now to avoid a disruption of your ASHI benefits!
Your ASHI Membership will expire on December 31, 2018. Your membership dues allow us to provide programs, professional awards, and educational opportunities that advance the science, education and application of immunogenetics and transplant immunology. Click here to renew today!
If you are experiencing trouble with your ASHI website username or password, contact Membership Coordinator, Mandi Cruz at email@example.com.
The Directors' Training Review and Credentialing Committee (DTRC), in addition to its role in evaluating future HLA Laboratory Directors, provides general follow-up and guidance to candidates at different stages of their training. One important aspect of any HLA Laboratory Director Training Program is the preparation of a portfolio of clinical cases to be submitted to the DTRC for assessment of the candidate’s competency as a future HLA Laboratory Director.
In an effort to help directors-in-training in preparing their portfolios, the DTRC has asked newly-approved candidates who submitted outstanding portfolio cases to share them. Some of these cases are presented in a new ASHI-U module, entitled "Volume 6." They are intended to provide directors-in-training with examples of case build-ups that meet or exceed portfolio reviewer expectations.
Click here to read more.
The ASHI Directors' Mentor / Mentee Program is dedicated to helping new directors advance in their careers. The program pairs new directors with more experienced directors on an informal basis for the purpose of providing one-on-one guidance and advice to the newer directors (mentees).
To become a Mentor, click here. To become a Mentee, click here.
Name & Credentials: Adam R. Blacker MS, CHS (ABHI), MLS (ASCP)
Title: Manager of HLA Services
Place of employment: Nevada Donor Network
Graduated from: Michigan State University
How long have you been an ASHI member? Since 2015
What made you decide to work in HLA? I worked in Dr. Gerlach's HLA Lab at Michigan State University during graduate school as a research assistant. He introduced me to the field and gave me opportunities to advance in a clinical laboratory specialty.
Click here to read more.
To be our next ASHI Member Spotlight, click here now! You can also nominate a co-worker or fellow colleague by contacting Mandi Cruz at Mcruz@ashi-hla.org.
2018 AC-2 Survey
AC-2 results are due by 11:59pm Pacific time on Friday, November 30, 2018.
2018 AC-1 Reports
The 2018 Summary and Performance Reports for the AC-1 survey are now available in the new PT Lab Center. To access the reports, login to the new Lab Center with your individual username and password, select Reports then Performance Reports.
The 2018 HT-2 review and grading process is underway. Email notifications will be sent to participating laboratories once the HT-2 report has been compiled.
The 2018 EMO-2 survey was shipped on Tuesday, November 6th. Results for EMO-2 are due by 11:59pm Pacific time Friday, December 7th.
One of the key conclusions from the first STAR meeting held in 2017 was that a major gap in risk stratification for organ transplantation is (lack of) knowledge, and more importantly, tools to detect potential of immune-memory responses prior to transplantation. Additionally, risk stratification and the immunobiology that leads to generation of de novo donor specific antibody production is poorly understood.
ASHI is proud to announce that it is supporting the 2019 STAR session which will be held just prior to the AST CEoT meeting in Feb 2019. The half day STAR 2019 meeting is designed to present current knowledge and have open discussions that will lead to the second STAR publication, with further recommendations for risk stratification.
The STAR 2019 Meeting will take place on Thursday, February 21st. To register for CEoT 2019 and the STAR 2019 Pre-Meeting, please click here.
Did you miss the ASHI 44th Annual Meeting in Baltimore? Purchase ASHI Access* now - recordings from the Annual Meeting - for only $75!
*Session recordings will be available to access approximately one month after the meeting ends. Only sessions where the speakers have given permission to share their presentations will be included.
ASHI Access is a comprehensive body of knowledge readily accessible to anyone needing information from the 44th Annual Meeting.
If you have any questions, please contact Victoria Ramsay at firstname.lastname@example.org.
- Convenient and easy to access audio synchronized to PowerPoint
- Broad range of materials consistent with today's latest research
- Includes access to most of the sessions from the 44th Annual Meeting including symposia, Hot Topics, Concurrent Oral Abstracts and Workshops
Check out the professional photos from the 2018 ASHI Annual Meeting in Baltimore. Click here to start viewing them. Feel free to save them, share them and post them to your social media using the hashtag #ASHIAnnual2018.
Mark your calendar now for future ASHI Annual Meetings!
45TH ANNUAL MEETING
September 23-27, 2019
David L. Lawrence Convention Center
46TH ANNUAL MEETING
October 19-23, 2020
Human leukocyte antigen-G (HLA-G) is a nonclassical Major Histocompatibility Complex (MHC) molecule with immunomodulatory function and restricted tissue expression. The genetic diversity of HLA-G has been extensively studied in several populations, however, the segment located upstream −1406 has not yet been evaluated.
Mesenchymal stromal/stem cells have immunosuppressive functions. Our previous results demonstrated that one of the players of this immunomodulation can be ascribed to the Human Leukocyte Antigen-G. HLA-G, a non classical HLA class I antigen, is involved in immune tolerance during pregnancy, organ transplantation, autoimmune and inflammatory diseases.
IL-8 is elevated during inflammation, and it initiates cascade of down-stream reactions. Its antagonist, CXCL8 (3–72) K11R/G31P (G31P), represses inflammatory reactions via competitive binding to CXC chemokine family, preferentially G protein-couple receptors (GPCRs) CXCR1/2. This study reports the effect of G31P on the transcription profile of lipopolysaccharide (LPS) induced inflammation in THP-1 monocytes ex-vivo.
American Journal of Transplantation
Should we continue to let positive complement‐dependent cytotoxicity (CDC) crossmatches be a reason we turn down organs for sensitized patients? Or can we safely manage or prevent the potential complications associated with transplanting across a positive crossmatch?
*As recommended by the Science & Technology Initiatives Committee
50 Minthorn Blvd.Suite 800, Thornhill, Ontario L3T 7X8